Serlin O, Keehn R J, Higgins G A, Harrower H W, Mendeloff G L
Cancer. 1977 Sep;40(3):1318-29. doi: 10.1002/1097-0142(197709)40:3<1318::aid-cncr2820400349>3.0.co;2-9.
This report is based on 903 patients with resections for gastric carcinoma between October 1957, and July 1969, entered in controlled trials of adjuvant therapy with Thio-TEPA and FUDR. Neither Thio-TEPA nor FUDR, as administered, prolonged survival. The extent of disease at the time of curative surgery is related to survival for the first 36 months postoperatively. Involvement of lymph nodes, resection of the esophagus, and serosal penetration are predictive of recurrence up to 36 months. There appear to be three groups of patients: 1) Cured (26%); 2) Slowly growing tumor--23% (median survival, 25 months); and 3) Rapidly growing tumor--51% (median survival, eight months). The absence of blood-vessel invasion, lymphatic invasion, lymph-node involvement, and serosal penetration characterize those patients in Group A.
本报告基于1957年10月至1969年7月间903例行胃癌切除术的患者，这些患者参与了硫替派和氟尿苷辅助治疗的对照试验。所给予的硫替派和氟尿苷均未延长生存期。根治性手术时的疾病范围与术后前36个月的生存期相关。淋巴结受累、食管切除和浆膜侵犯可预测36个月内的复发情况。患者似乎可分为三组：1）治愈组（26%）；2）肿瘤生长缓慢组——23%（中位生存期25个月）；3）肿瘤生长迅速组——51%（中位生存期8个月）。A组患者的特征为无血管侵犯、淋巴侵犯、淋巴结受累和浆膜侵犯。
